Kidiamix G

Valine, Acetylcysteine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, the active ingredients in Kidiamix G, are amino acids presented as a solution for injection for intravenous use. It supports protein synthesis and provides essential amino acids for patients unable to receive enteral feeding.

GNH USA supplies Kidiamix G as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kidiamix G is used in the context of parenteral nutrition to address protein and amino‑acid needs in patients who cannot be fed enterally. - Parenteral nutrition: provides essential amino acids for patients who cannot receive enteral feeding. - Critical illness support: assists protein synthesis and nitrogen balance in ICU patients. - Post‑operative care: helps prevent amino‑acid deficiency after major surgery.

Kidiamix G may be associated with infusion‑related reactions and metabolic changes.

Common Side Effects: - Phlebitis at the infusion site - Mild fever or chills - Nausea or vomiting - Headache - Transient hyperglycemia - Electrolyte shifts (e.g., mild hypokalemia)

Serious or Rare Side Effects: - Anaphylactic reaction - Severe hypotension - Metabolic acidosis - Hepatic dysfunction - Acute renal failure - Severe electrolyte disturbances (e.g., hypernatremia)

Kidiamix G requires careful monitoring in several clinical situations. - Renal impairment: monitor renal function and adjust infusion rate. - Hepatic dysfunction: use with caution; assess liver enzymes. - Electrolyte balance: regularly check serum electrolytes. - Metabolic disorders: evaluate nitrogen balance and acid‑base status. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kidiamix G can interact with other therapies that affect amino‑acid or electrolyte homeostasis.

Major Interactions (Avoid): - Concurrent high‑dose amino‑acid solutions: risk of overload and metabolic imbalance. - Renal replacement therapy: may remove administered amino acids, reducing efficacy. - Insulin therapy: may potentiate hypoglycemia when combined with glucose‑containing solutions.

Moderate Interactions (Monitor Closely): - Electrolyte‑containing medications: monitor serum levels for additive effects. - Diuretics: may exacerbate electrolyte loss. - Certain chemotherapeutic agents: may alter protein metabolism and require dose adjustment.